LEPU BIO-B (02157) announced on November 28, 2025, that the company has signed a CDMO service framework agreement with Lepu Medical Technology (Beijing) Co., Ltd. Under the agreement, LEPU BIO-B and/or its subsidiaries will provide CDMO technical services to Lepu Medical and/or its affiliates.
Beyond meeting its own clinical trial and commercialization demands for drug production, the group can now utilize excess capacity more efficiently when suitable business opportunities arise. The board believes that this agreement will optimize the use of surplus production capabilities and generate supplementary cash flow for the group.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments